TG Therapeutics, Inc.
$63.34-$1.54 (-2.4%)
Last close · Data as of Nov 20, 2026
- Market cap
- $6.2B
- P/E
- 13.9x
- EV / EBITDA
- 47.5x
- Revenue
- $616.3M
- Net margin
- 72.6%
- ROCE
- 13.6%
Price chart
Technical chartScreen technicals →+108.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +16.2%
- 3M
- +25.3%
- 6M
- +59.3%
- 1Y
- +108.0%
- 5Y
- +159.5%
52-week range
Day change -$1.54 (-2.4%) from $65 to $63 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in TGTX, bought on each weekday since 2021.
News & filings
What TG Therapeutics filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernOperating cash flow was -24.8 million US dollars in fiscal 2025, a year of net profit.
Strengths (1)
- Net margin of 72.6% against a peer median of 9.3%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Read moreShow less
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
- Sector
- Healthcare
- Shares outstanding
- 144.3M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $6.2B
- P/E
- 13.9x
- P/B
- 9.6x
- EV / EBITDA
- 47.5x
- EV / Sales
- 10.4x
- P/S
- 10.1x
- 52-week high
- $66.12
- 52-week low
- $26.94
Profitability
- Operating margin
- 20.0%
- Net margin
- 72.6%
- EBITDA margin
- 21.8%
- ROE
- 69.0%
- ROCE
- 13.6%
- ROA
- 42.1%
- Asset turnover
- 0.58
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $616.3M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 87.3%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 504.9%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 1812.4%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$25.0M
Solvency
- Current ratio
- 4.10
- Debt / Equity
- 0.39
- Debt / Assets
- 0.24
- CFO / Net profit
- -0.06
- Cash / Market cap
- 1.3%
Where the revenue went
Of every $100 of FY2025 revenue, $73 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $100.7M |
| Revenue | Gross profit | $515.6M |
| Gross profit | Research and development | $160.2M |
| Gross profit | Selling, general and administrative | $232.0M |
| Gross profit | Other operating expenses | $10.0k |
| Gross profit | Operating income | $123.3M |
| Operating income | Pretax income | $107.4M |
| Operating income | Interest and other expense | $15.9M |
| Pretax income | Net income | $107.4M |
| Tax benefit and other | Net income | $339.8M |
Revenue and net profit
Revenue grew 87.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $2.8M | -$223.8M |
| FY2023 | $233.7M | $12.7M |
| FY2024 | $329.0M | $23.4M |
| FY2025 | $616.3M | $447.2M |
Cash flows
FY2025: -$24.8M from operations, -$25.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$176.2M | -$176.2M |
| FY2023 | -$31.4M | -$31.4M |
| FY2024 | -$40.5M | -$40.6M |
| FY2025 | -$24.8M | -$25.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $616.3M+87.3%1Y
- EBITDA
- $134.4M+169.2%1Y
- Net profit
- $447.2M+1,812.4%1Y
- Cash from operations
- -$24.8M
- Free cash flow
- -$25.0M
- Revenue CAGR, 3Y
- 504.9%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $616.3M | $134.4M | $447.2M | -$25.0M | 69.0% | +87.3% | +1812.4% |
Monthly returns
Month-by-month returns of TGTX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.1B |
| Current assets | $630.8M |
| Non-current assets | $432.5M |
| Liabilities | $415.2M |
| Current liabilities | $153.8M |
| Non-current liabilities | $261.5M |
| Equity | $648.0M |
| Paid-in capital | $1.8B |
| Retained earnings | -$1.1B |
| Treasury stock | $100.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; TGTX highlighted.
P/E against peers
TGTX trades at 13.9x earnings against a peer median of 14.8x.
Not shown (no positive earnings and no EV / Sales): Glaukos Corporation, Protagonist Therapeutics, Inc., Teleflex Incorporated.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| TG Therapeutics, Inc.TGTXthis company | $6.2B | 13.9x | 9.6x | 69.0% | 47.5x |
| Alkermes plcALKS | $7.2B | 29.9x | 4.0x | 13.3% | 20.9x |
| Glaukos CorporationGKOS | $7.1B | -38.1x | 10.9x | -28.6% | -49.0x |
| Protagonist Therapeutics, Inc.PTGX | $6.6B | -50.8x | 10.8x | -21.2% | -41.4x |
| PTC Therapeutics, Inc.PTCT | $5.9B | 8.6x | — | -332.5% | 7.5x |
| Teleflex IncorporatedTFX | $5.8B | -6.5x | 1.9x | -29.0% | 27.1x |
| Apellis Pharmaceuticals, Inc.APLS | $5.3B | 234.6x | 14.2x | 6.0% | 75.2x |
| Ligand Pharmaceuticals IncorporatedLGND | $4.7B | 38.0x | 4.6x | 12.2% | 25.3x |
| Indivior Pharmaceuticals, Inc.INDV | $4.4B | 21.1x | -44.7x | -212.1% | 15.1x |
| Peer median | — | 14.8x | 4.6x | -24.9% | 18.0x |
Year-to-date ROI
TGTX since 1 January, against earlier years.
Historical volatility
TGTX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -7853.2% |
| FY2023 | 8.8% |
| FY2024 | 12.7% |
| FY2025 | 20.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $616.3M |
| Cost of revenueCost Of Revenue | $100.7M |
| Gross profitGross Profit | $515.6M |
| Operating expensesOperating Expense | $392.3M |
| Research and developmentResearch And Development | $160.2M |
| Selling, general and administrativeSelling General And Administration | $232.0M |
| Total expensesTotal Expenses | $493.0M |
| Operating incomeOperating Income | $123.3M |
| Interest and other | |
| Pretax incomePretax Income | $107.4M |
| TaxTax Provision | -$339.8M |
| Net incomeNet Income | $447.2M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.1B |
| Current assetsCurrent Assets | $630.8M |
| Non-current assetsTotal Non Current Assets | $432.5M |
| LiabilitiesTotal Liabilities Net Minority Interest | $415.2M |
| Current liabilitiesCurrent Liabilities | $153.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $261.5M |
| EquityTotal Equity Gross Minority Interest | $648.0M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$24.8M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$24.8M |
| Net income, continuing operationsNet Income From Continuing Operations | $447.2M |
| Depreciation and amortisationDepreciation And Amortization | $240.0k |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $240.0k |
| Depreciation | $240.0k |
| Amortization of securitiesAmortization Of Securities | -$3.8M |
| Stock-based compensationStock Based Compensation | $64.7M |
| Deferred taxDeferred Tax | -$348.0M |
| Deferred income taxDeferred Income Tax | -$348.0M |
| Operating gains and lossesOperating Gains Losses | — |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | $300.0k |
| Provision and write off of assetsProvisionand Write Offof Assets | $6.2M |
| Change in working capitalChange In Working Capital | -$194.5M |
| Other non-cash itemsOther Non Cash Items | $3.0M |
| Investing cash flowInvesting Cash Flow | $13.8M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $13.8M |
| Capital expenditureCapital Expenditure | -$210.0k |
| Purchase of PP&EPurchase Of PPE | -$210.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$210.0k |
| Purchase of investmentsPurchase Of Investment | -$223.5M |
| Sale of investmentsSale Of Investment | $237.5M |
| Net investment purchases and salesNet Investment Purchase And Sale | $14.0M |
| Financing cash flowFinancing Cash Flow | -$89.7M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$89.7M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | $0.00 |
| Net debt issuedNet Issuance Payments Of Debt | $0.00 |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | $0.00 |
| Net long-term debt issuedNet Long Term Debt Issuance | $0.00 |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | -$91.2M |
| Common stock repurchasedCommon Stock Payments | -$91.2M |
| Share buybacksRepurchase Of Capital Stock | -$91.2M |
| Stock options exercisedProceeds From Stock Option Exercised | $1.5M |
| Dividends paidCash Dividends Paid | — |
| Other financing chargesNet Other Financing Charges | — |
| Interest paid (financing)Interest Paid Cff | — |
| Change in cashChanges In Cash | -$100.7M |
| Cash at the start of the yearBeginning Cash Position | $181.2M |
| Cash at the end of the yearEnd Cash Position | $80.5M |
| Free cash flowFree Cash Flow | -$25.0M |
| Supplemental |
Learn while you research
Academy chapters picked for TG Therapeutics, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing87% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read